| Nevus |
NCT02147951: Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma |
|
|
| No Longer Available | 3b | | US | Talimogene Laherparepvec | Amgen | Unresected Stage IIIb to IVM1c Melanoma | | | | |
| Not yet recruiting | 3 | 10500 | Europe | Surgical Excision Margin | Norfolk and Norwich University Hospitals NHS Foundation Trust, Australia & New Zealand Melanoma Trials Group | Melanoma | | | | |
NCT02258243: Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome |
|
|
| Active, not recruiting | 2 | 3 | US | aminolevulinic acid hydrochloride, 5-ALA HCl, ALA HCl, aminolevulinic acid HCl, photodynamic therapy, Light Infusion Therapy™, PDT, therapy, photodynamic, laboratory biomarker analysis, questionnaire administration | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Basal Cell Carcinoma of the Skin, Nevoid Basal Cell Carcinoma Syndrome | 10/16 | 12/17 | | |
| No Longer Available | N/A | | US | CP-675,206 | Pfizer | Advanced Unresectable Melanoma | | | | |
NCT01005537: Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma |
|
|
| No Longer Available | N/A | | US | aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Melanoma (Skin) | 10/10 | | | |
NCT00495066: Compassionate Use Trial for Unresectable Melanoma With Ipilimumab |
|
|
| No Longer Available | N/A | | RoW | Ipilimumab | Bristol-Myers Squibb | Melanoma | | | | |
|
|
|
|
|
|
|
|
|
NCT01338389: Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy |
|
|
| Completed | N/A | 21 | Europe | CITICOLINE, PLACEBO | Centre Hospitalier Universitaire de Nice, DENSMORE pharmaceuticals | Uveal Melanoma | 06/17 | 06/17 | | |
NCT01728051: Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver |
|
|
| No Longer Available | N/A | | US | Melphalan, Percutaneous Hepatic Perfusion | Delcath Systems Inc. | Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma | | | | |
CheckMate 218, NCT02186249: Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma |
|
|
| No Longer Available | N/A | | US, Canada | Nivolumab, Ipilimumab | Bristol-Myers Squibb | Malignant Melanoma | | | | |
|
NCT02083484: Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) |
|
|
| No Longer Available | N/A | | NA | Pembrolizumab | Merck Sharp & Dohme LLC | Melanoma | | | | |
|
|
|
| No Longer Available | N/A | | US, Canada, RoW | Nivolumab | Bristol-Myers Squibb | Stage III (Unresectable) or Stage IV Advanced Melanoma | 05/18 | 05/18 | | |
| Active, not recruiting | N/A | 296 | Europe | | European Organisation for Research and Treatment of Cancer - EORTC | Cutaneous Melanoma | 12/23 | 12/31 | | |
NCT00872391: Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma |
|
|
| Recruiting | N/A | 155 | Europe | Hypofractionated linear accelerator radiotherapy | Medical University of Vienna | Uveal Melanoma | 03/24 | | | |
NCT01438658: Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma |
|
|
| Recruiting | N/A | 250 | RoW | | Hadassah Medical Organization | Uveal Melanoma | 12/40 | 12/40 | | |